BCAB
BioAtla, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-0.18
P/S
3.32
EV/EBITDA
-0.10
DCF Value
$-5.01
FCF Yield
-512.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-2965.3%
Net Margin
-2980.3%
ROE
285.1%
ROA
-431.1%
ROIC
889.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $2.0M | $-9.8M | $-0.16 |
| FY 2025 | $2.0M | $-59.6M | $-1.01 |
| Q3 2025 | $0.00 | $-15.8M | $-0.27 |
| Q2 2025 | $0.00 | $-18.7M | $-0.32 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$5.00 - $5.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.07
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.